Use of tetrahydropyridines in the treatment of central nervous system disorders
View Patent ↗Disclosed are methods for alleviating symptoms of neuropsychiatric disorders using tetrahydropyridine derivatives bearing aromatic substituents. The method comprises administering to an individual a tetrahydropyridine derivative bearing aromatic substituents in an amount effective to alleviate symptoms of the neuropsychiatric disorder.
1. A method for alleviating one or more symptoms of a neuropsychiatric disorder in an individual, wherein the neuropsychiatric disorder is schizophrenia, the method comprising administering to the individual a composition comprising a compound in an amount effective to alleviate the symptoms of the neuropsychiatric disorder, wherein the compound has the following structure (2):
its enantiomer, or racemic mixtures thereof; wherein R can be such that the R-bearing ring is mono-, di- or tri-substituted, and in which the substituents consist of hydrogen, alkyl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate, or a combination thereof, and wherein the administration of the composition alleviates one or more symptoms of the neuropsychiatric disorder.
2. The method of claim 1 wherein R is one or more substituents selected from the group consisting of hydrogen, substituted or unsubstituted phenyls, halogens, and adjacent rings which share a side with the R-bearing phenyl group.
3. The method of claim 1 , wherein R is a p-bromo.
4. The method of claim 1 , wherein R is a p-chloro.
5. The method of claim 1 , wherein R is an unsubstituted p-phenyl.
6. The method of claim 1 , wherein R consists of chlorine substituents at positions 3 and 4.
7. The method of claim 1 , wherein R is a p-2-naphthyl.
8. A method for alleviating one or more symptoms of a neuropsychiatric disorder in an individual, wherein the neuropsychiatric disorder is schizophrenia, the method comprising administering to the individual a composition comprising a compound in an amount effective to alleviate the symptoms of the neuropsychiatric disorder, wherein the compound has the threo-diasteromeric structure of following structure (2):
or a diastereomeric mixture of said threo-diastereomer and its erythro diastereomer; wherein R can be such that the R-bearing ring is mono-, di- or tri-substituted, and in which the substituents consist of hydrogen, alkyl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate, or a combination thereof, and wherein the administration of the composition alleviates one or more symptoms of the neuropsychiatric disorder.
9. The method of claim 8 wherein R is one or more substituents selected from the group consisting of hydrogen, substituted or unsubstituted phenyls, halogens, and adjacent rings which share a side with the R-bearing phenyl group.
10. The method of claim 8 , wherein R is a p-bromo.
11. The method of claim 8 , wherein R is a p-chloro.
12. The method of claim 8 , wherein R is an unsubstituted p-phenyl.
13. The method of claim 8 , wherein R consists of chlorine substituents at positions 3 and 4.
14. The method of claim 8 , wherein compound 2 is:
15. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
16. The method of claim 8 , wherein the composition is administered via a route selected from the group consisting of orally, parenterally, intramuscularly, intravenously, mucosally and transdermally.
17. The method of claim 8 , wherein the composition is administered orally.